Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of adjuvanted cell-derived inactivated A/H1N1 influenza vaccine in healthy Japanese adults
jRCT2080221031Phase 3
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of adjuvanted cell-derived inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine in influenza A virus infection (H1N1), sponsored by Novartis. Primary endpoints: Primary immunogenicity endpoints and Primary safety and tolerability endpoints.
02
Drugs
adjuvanted cell-derived inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
03
Conditions
influenza A virus infection (H1N1)
Beyond the preview
Go deeper on jRCT2080221031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221031.